| Literature DB >> 35707272 |
Izabela Kokot1, Sylwester Mazurek2, Agnieszka Piwowar3, Roman Szostak2, Marcin Jędryka4,5, Ewa Maria Kratz1.
Abstract
Endometriosis is one of the most common gynecological diseases among young women of reproductive age. Thus far, it has not been possible to define a parameter that is sensitive and specific enough to be a recognized biomarker for diagnosing this disease. Nonspecific symptoms of endometriosis and delayed diagnosis are impulses for researching noninvasive methods of differentiating endometriosis from other gynecological disorders. We compared three groups of individuals in our research: women with endometriosis (E), patients suffering from other gynecological disorders (nonendometriosis, NE), and healthy women from the control group (C). Partial least squares discriminant analysis (PLS-DA) models were developed based on selected serum biochemical parameters, specific regions of the serum's infrared attenuated total reflectance (FTIR ATR) spectra, and combined data. Incorporating the spectral data into the models significantly improved differentiation among the three groups, with an overall accuracy of 87.5%, 97.3%, and 98.5%, respectively. This study shows that infrared spectroscopy and discriminant analysis can be used to differentiate serum samples among women with advanced endometriosis, women without this disease, i.e., healthy women, and, most importantly, also women with other benign gynecological disorders.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35707272 PMCID: PMC9192200 DOI: 10.1155/2022/4777434
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 7.310
Serum biochemical parameters for the studied groups.
| Endometriosis | Nonendometriosis | Control | |
|---|---|---|---|
| Mean ± SD | Mean ± SD | Mean ± SD | |
| PRL (ng/mL) | 29.01 ± 18.71 | 27.02 ± 18.62 | 12.84 ± 4.86 |
| CA 125 (U/mL) | 113.41 ± 129.42 | 23.64 ± 17.39 | 14.28 ± 7.40 |
| IgG (mg/dL) | 1065.46 ± 286.73 | 1078.22 ± 298.25 | 1237.28 ± 215.91 |
| hsCRP (mg/L) | 14.29 ± 19.45 | 13.88 ± 19.96 | 0.96 ± 1.19 |
| Albumin (g/dL) | 4.36 ± 0.64 | 4.13 ± 0.32 | 4.26 ± 0.19 |
| Calcium (mg/dL) | 9.62 ± 1.15 | 9.35 ± 0.49 | 9.29 ± 0.25 |
| Magnesium (mg/dL) | 2.44 ± 0.37 | 2.47 ± 0.18 | 2.22 ± 0.14 |
| hsIL-1 | 0.57 ± 0.39 | 0.56 ± 0.46 | 0.27 ± 0.26 |
| IL-6 (pg/ml) | 19.33 ± 43.69 | 18.05 ± 34.09 | 1.47 ± 1.48 |
| FRAP (mmol/L) | 1.11 ± 0.26 | 1.18 ± 0.30 | 0.95 ± 0.22 |
| AOPP ( | 235.16 ± 150.41 | 181.78 ± 156.00 | 105.16 ± 49.24 |
| YKL-40 (ng/mL) | 685.22 ± 1246.58 | 403.29 ± 934.76 | 104.12 ± 154.07 |
AOPP: advanced protein oxidation products; CA 125: carcinoma antigen 125; FRAP: ferric-reducing antioxidant power; hsCRP: high sensitive C-reactive protein; hsIL-1β: high sensitive interleukin 1β; IgG: immunoglobulin G; IL-6: interleukin 6; PRL: prolactin; YKL-40: chitinase-3-like protein 1. Data presented in the table are a part of previously published study results [2, 26].
Figure 1Score plots for PLS-DA modeling of biochemical data from serum samples: (a) all parameters included (n = 29) and (b) iPLS variable selection (n = 6). E: endometriosis; NE: nonendometriosis; C: control group of healthy women.
Parameters of PLS-DA models.
| Parameter | Biochemistry | FTIR ATR | Fused data | ||||||
|---|---|---|---|---|---|---|---|---|---|
| E | NE | C | E | NE | C | E | NE | C | |
| Accuracy | 92.2 (87.5) | 92.2 (85.9) | 90.6 (89.1) | 98.6 (92.9) | 97.1 (92.9) | 98.6 (94.3) | 98.5 (94.1) | 98.5 (95.6) | 100 (98.5) |
| Sensitivity (TPR) | 80.8 (76.9) | 90.0 (75.0) | 94.4 (94.4) | 96.6 (89.7) | 95.8 (91.7) | 100 (88.2) | 96.3 (92.6) | 100 (91.3) | 100 (100) |
| Specificity (TNR) | 100 (94.7) | 93.2 (90.9) | 89.1 (87.0) | 100 (95.1) | 97.8 (93.5) | 98.1 (96.2) | 100 (95.1) | 97.8 (97.8) | 100 (98.0) |
| Precision (PPV) | 100 (90.9) | 85.7 (78.9) | 77.3 (73.9) | 100 (92.9) | 95.8 (88.0) | 94.4 (88.2) | 100 (92.6) | 95.8 (95.5) | 100 (94.7) |
| F1-score | 89.4 (83.3) | 87.8 (76.9) | 85.0 (82.9) | 98.2 (91.2) | 95.8 (89.8) | 97.1 (88.2) | 98.1 (92.6) | 97.9 (93.3) | 100 (97.3) |
| Overall accuracy | 87.5 (81.3) | 97.3 (89.9) | 98.5 (94.3) | ||||||
E: endometriosis; NE: nonendometriosis; C: control group of healthy women; TPR: true positive rate; TNR: true negative rate; PPV: positive predictive value. In parenthesis, the results of cross-validation are shown.
Figure 2Average FTIR ATR spectra of sera in the 700-1450 cm−1 range for the three studied groups (a) and the second derivatives of the spectra (b); the black dots indicate variables selected by iPLS for the PLS-DA model. E: endometriosis; NE: nonendometriosis; C: control group of healthy women; cm−1: unit of the wavenumbers presented as the reciprocal centimeters.
Figure 3PLS-DA score plots obtained for the ATR spectra of the serum samples for the model applying the 700-1450 cm−1 range (a) and the model with variables selected via iPLS (b). E: endometriosis; NE: nonendometriosis; C: control group of healthy women.
Figure 4Representative input for fused data.
Figure 5ROC curves (a) and scores plot (b) for the PLS-DA model based on the fused data. E: endometriosis; NE: nonendometriosis; C: control group of healthy women.